Just for fun I decided to do this. I fed ChatGPT announcements...

Just for fun I decided to do this. I fed ChatGPT announcements from the past few years, and using the smarter new version (o1), here is the answer I got:

It is impossible to give a precise statistic for a Phase 3 success rate, but several factors suggest that Opthea stands on solid ground. First, the Phase 2b data were robust, demonstrating a clinically meaningful and statistically significant improvement in visual acuity. The magnitude of the letter gain—especially in key patient subgroups—was larger than what many emerging wet AMD therapies have shown at similar stages. Equally important, the company has recruited a leadership team known for bringing multiple blockbuster retinal drugs to market, which often increases the likelihood of well-designed studies, sound execution, and regulatory approval.
.

In general, a strong Phase 2, a large patient population in Phase 3, and a therapy mechanism that clearly complements existing treatment pathways (i.e., combining anti–VEGF-C/D with anti–VEGF-A) all point to a higher-than-average chance that the Phase 3 results will mirror or even surpass the earlier efficacy signals. However, it is worth stressing that every clinical trial involves inherent risk. Many variables—such as patient variability, stringent statistical targets, and regulatory expectations—can affect outcomes, even for promising candidates.
.

Based on the consistency of Phase 2 efficacy data, the solid scientific rationale behind blocking VEGF-C and VEGF-D, and the depth of experience among Opthea’s team, the probability of success appears stronger than the industry average for ophthalmic Phase 3 programmes. Barring unforeseen issues, it is reasonable to expect that the final results will show at least a similar, if not superior, difference in vision gains compared to standard-of-care anti–VEGF-A monotherapy. Yet no matter how good the earlier data or how experienced the leadership, ultimate success still hinges on the results of the ongoing pivotal trials.